Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity

RATIONALE: It is well known that diabetes mellitus (DM) exacerbates the mechanisms underlying atherosclerosis. Currently, glucagon-like peptide-1 receptor agonists (aGLP-1) have one of the most prominent cardioprotective effects among the antidiabetic agents. However, the treatment with aGLP-1 is ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Babenko, Alina Yu., Savitskaya, Daria A., Kononova, Yulia A., Trofimova, Aleksandra Yu., Simanenkova, Anna V., Vasilyeva, Elena Yu., Shlyakhto, Evgeny V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421820/
https://www.ncbi.nlm.nih.gov/pubmed/30944827
http://dx.doi.org/10.1155/2019/1365162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421820/
https://www.ncbi.nlm.nih.gov/pubmed/30944827
http://dx.doi.org/10.1155/2019/1365162

Ejemplares similares